Bellevue Asset Management, LLC Revance Therapeutics, Inc. Transaction History

Bellevue Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$5.81 - $11.2 $261 - $503	45 Added 48.39%	138 $1,000
Q1 2023 May 09, 2023	BUY	$18.36 - $35.27 $312 - $599	17 Added 22.37%	93 $2,000
Q1 2022 May 11, 2022	SELL	$12.36 - $20.31 $197 - $324	-16 Reduced 17.39%	76 $1,000
Q4 2021 Feb 03, 2022	SELL	$12.46 - $27.87 $87 - $195	-7 Reduced 7.07%	92 $2,000
Q2 2021 Aug 09, 2021	SELL	$26.8 - $31.84 $241 - $286	-9 Reduced 8.33%	99 $3,000
Q1 2021 May 12, 2021	SELL	$24.03 - $29.97 $360 - $449	-15 Reduced 12.2%	108 $3,000
Q4 2020 Feb 11, 2021	BUY	$23.41 - $28.34 $1,310 - $1,587	56 Added 83.58%	123 $3,000
Q1 2020 May 13, 2020	BUY	$12.46 - $27.81 $423 - $945	34 Added 103.03%	67 $1,000
Q4 2019 Feb 13, 2020	BUY	$11.66 - $20.15 $384 - $664	33 New	33 $1,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Bellevue Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bellevue Asset Management, LLC with notifications on news.